A Retrospective Study on the Effect of Male Progressive Sperm Count After Semen Pretreatment on ICSI Fertilization Outcome

The investigators plan to retrospectively analyze clinical data from 14,189 fresh ICSI cycles in Reproductive and Genetic Hospital of CITIC-Xiangya from January 2016 to December 2017.The investigators will regard total progressive sperm number of 2 x 10^6 after pretreatment as the boundary value, and will divide total progressive sperm number of 2 x 10^6 after pretreatment into 2 x 10^6 or higher and < 2 x 10^6 groups, and will further divide < 2 x 10^6 group into: = 0, (0,10^6], (10^6, 2 x 10^6) three groups. Propensity score matching will be used to balance the baseline data between four groups. The matching variables are age, female BMI, AFC, AMH and ICSI.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Sperm Count, Low Genital Diseases Genital Diseases, Male Infertility Infertility, Male Male Urogenital Diseases Oligospermia Reproductive Sterility Urogenital Diseases

Sex eligibility

All sexes

Study type

Observational

Primary location

Reproductive & Genetic Hospital of CITIC-XIANGYA

Changsha, Hunan, 410008, China

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

infertility female and sterility male for reproductive treatment

Exclusion criteria

chromosomal abnormalities
none retrieval oocyte
none oocyte for ICSI
Recurrent abortion
female age≥37 years
Assisted hatching
abnormal oocyte zona pellucida
In Vitro Maturation
AZF microdeletion

Treatment and study plan

semen pretreatment

Other

semen pretreatment

Primary outcomes

high quality embryo rate for ICSI

Time frame: two years

rate of embryo grade above 6CI on the third day after fertilization

Secondary outcomes

fertilization rate of ICSI

Time frame: two years

number of fertilized oocytes/ number of metaphase II oocytes
normal fertilization rate of ICSI

Time frame: two years

number of 2PN fertilized oocytes/ number of metaphase II oocytes

Sponsors and collaborators

Lead sponsor

Reproductive & Genetic Hospital of CITIC-Xiangya

Other

Registry information

Important dates

Study start: 2016
Primary completion: 2017
Study completion: 2018
First posted: Jul 20, 2018
Registry last updated: May 21, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed